Shots:
- Unnatural Products has entered a research collaboration & licensing agreement with Novartis for an undisclosed cardiovascular program developed using UNP’s AI-enhanced macrocycle platform
- Under the deal, Novartis will handle IND-enabling studies & subsequent clinical development, manufacturing, & global commercialization of products emerging from the collaboration
- As per the terms, UNP will receive ~$100M in upfront & pre-IND milestone payments & ~$1.7B in development, regulatory, & commercial milestones, with tiered royalties mid-single up to low double-digits on annual net sales
Ref: Globenewswire | Image: UNP & Novartis | Press Release
Related News: Unnatural Products Collaborates with argenx to Develop Oral Macrocyclic Peptides Across Multiple Indications
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
